Gilead's Yescarta rebuffed by NICE, second orphan drug setback in August

One day after the European Commission approved CAR T therapy Yescarta axicabtagene ciloleucel from the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD), U.K.'s NICE published draft guidance recommending against the use of therapy. The guidance applies to adults with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who have received two or more lines

Read the full 579 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE